Cibc World Markets Corp Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Cibc World Markets Corp grew its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 133.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 102,906 shares of the company’s stock after acquiring an additional 58,894 shares during the quarter. Cibc World Markets Corp’s holdings in Eli Lilly and Company were worth $59,986,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $26,000. Tidemark LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $29,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at $36,000. St. Johns Investment Management Company LLC lifted its position in shares of Eli Lilly and Company by 123.3% in the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after acquiring an additional 37 shares in the last quarter. Finally, O Brien Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.7 %

Shares of LLY stock traded up $5.53 during trading hours on Thursday, reaching $837.29. The company had a trading volume of 2,106,316 shares, compared to its average volume of 2,956,611. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a twelve month low of $432.34 and a twelve month high of $846.97. The company has a market capitalization of $795.76 billion, a P/E ratio of 123.31, a price-to-earnings-growth ratio of 1.82 and a beta of 0.36. The stock’s fifty day simple moving average is $774.36 and its 200 day simple moving average is $706.18.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the firm earned $1.62 earnings per share. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, sell-side analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.62%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 20,383 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $836.32, for a total transaction of $17,046,710.56. Following the completion of the sale, the insider now owns 98,188,427 shares in the company, valued at approximately $82,116,945,268.64. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 20,383 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $836.32, for a total transaction of $17,046,710.56. Following the completion of the sale, the insider now owns 98,188,427 shares in the company, valued at approximately $82,116,945,268.64. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 337,804 shares of company stock worth $278,236,284. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Argus increased their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Truist Financial increased their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Finally, Bank of America increased their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $769.53.

View Our Latest Analysis on LLY

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.